Birgit Ehlken
IMS Health
42 Papers
295 Citations
Birgit Ehlken is an academic researcher from IMS Health. The author has contributed to research in topics: Medicine & Rotavirus. The author has an hindex of 18, co-authored 41 publications.
Chat about Author
Papers
Cost of illness of atopic asthma and seasonal allergic rhinitis in Germany: 1‐yr retrospective study
TL;DR: The total cost for patients increases with the severity of atopic asthma and/or seasonal allergic rhinitis and indirect costs represent a large proportion of the total cost.
159
The impact of delayed chemotherapy-induced nausea and vomiting on patients, health resource utilization and costs in German cancer centers
Angela Ihbe-Heffinger,Birgit Ehlken,Rudolf Bernard,Karin Berger,Christian Peschel,H.-G. Eichler,H.-G. Eichler,R. Deuson,J. Thödtmann,Florian Lordick +9 more
TL;DR: The greatest improvements in patient care and potential for cost offset may be realized by preventing delayed CINV, and highlights a continuing need for improved utilization of existing antiemetic agents and for new, more efficacious treatments.
145
International variation in disease burden of rotavirus gastroenteritis in children with community- and nosocomially acquired infection.
Martin Fruhwirth,Ulrich Heininger,Birgit Ehlken,Gundula Petersen,Birgit Laubereau,Ingrid Moll-Schuler,Ingomar Mutz,J Forster +7 more
TL;DR: The cumulative experience from three European countries suggest that rotavirus is an important cause of diarrhea in Central Europe, but significant local differences clearly demonstrate the need for obtaining national data as a reliable basis for control and prevention of the disease.
111
Cost-of-illness in patients with moderate and severe chronic psoriasis vulgaris in Germany
TL;DR: The aim of this study was to assess average annual cost and cost per flare of outpatient and office‐based care for patients with moderate to severe chronic psoriasis vulgaris from several perspectives.
103
Treatment outcomes and resource use of patients with neurogenic detrusor overactivity receiving botulinum toxin A (BOTOX®) therapy in Germany
B. Wefer,Birgit Ehlken,Jörn Bremer,H. Burgdörfer,Burkhard Domurath,Christian Hampel,Johannes Kutzenberger,C. Seif,Karl D. Sievert,Karin Berger,Jürgen Pannek +10 more
TL;DR: This is the first study demonstrating the clinical usefulness of Botox® therapy in clinical practice, and successful treatment resulted in lower costs for NDO associated morbidity due to less need for incontinence aids and UTI medication.
55